Compare DSS & BIAF Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Current Price
| Metric | DSS | BIAF |
|---|---|---|
| Founded | 1984 | 2014 |
| Country | United States | United States |
| Employees | N/A | 57 |
| Industry | Containers/Packaging | Biotechnology: In Vitro & In Vivo Diagnostic Substances |
| Sector | Consumer Discretionary | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 5.3M | 4.6M |
| IPO Year | 2020 | N/A |
| Metric | DSS | BIAF |
|---|---|---|
| Price | $0.49 | $1.67 |
| Analyst Decision | | |
| Analyst Count | 0 | 0 |
| Target Price | N/A | N/A |
| AVG Volume (30 Days) | 36.5K | ★ 179.3K |
| Earning Date | 05-15-2026 | 05-14-2026 |
| Dividend Yield | N/A | N/A |
| EPS Growth | ★ 42.45 | N/A |
| EPS | N/A | ★ N/A |
| Revenue | ★ $2,085,000.00 | N/A |
| Revenue This Year | $1.21 | $20.95 |
| Revenue Next Year | N/A | N/A |
| P/E Ratio | ★ N/A | N/A |
| Revenue Growth | N/A | ★ N/A |
| 52 Week Low | $0.47 | $0.23 |
| 52 Week High | $1.90 | $13.50 |
| Indicator | DSS | BIAF |
|---|---|---|
| Relative Strength Index (RSI) | 41.31 | 38.53 |
| Support Level | N/A | $1.26 |
| Resistance Level | $1.04 | $1.79 |
| Average True Range (ATR) | 0.04 | 0.18 |
| MACD | 0.01 | 0.03 |
| Stochastic Oscillator | 61.06 | 36.13 |
DSS Inc is operating a business focused on four operating segments: Product Packaging, Biotechnology, Commercial Lending, and Securities and Investment Management. Currently operates five distinct business lines that operate around the globe with primary operations in North America and Asia. Product packaging manufactures and sells sophisticated custom folding cartons, mailers, photo sleeves, and complex three-dimensional direct mail solutions. The biotechnology division targets unmet, urgent medical needs and expands the borders of medical and pharmaceutical science. Commercial Lending represents its banking and financing business line. Alternative Trading develops and/or acquires assets and investments in the Securities and Investment Management.
bioAffinity Technologies Inc addresses the need for noninvasive diagnosis of early-stage cancer and diseases of the lung and targeted cancer treatment. It develops proprietary noninvasive diagnostic tests and cancer therapeutics using technology that preferentially targets cancer cells and cell populations indicative of a diseased state. The company's product, CyPath Lung, is a noninvasive test for the detection of early-stage lung cancer.